Dainippon Sumitomo To Conduct Trials Outside Japan
This article was originally published in PharmAsia News
Japan's Dainippon Sumitomo Pharma became the latest drug maker to announce it would shift some of its clinical trials to other Asian nations. Dainippon said that among the drugs being developed for the Japanese market is its antipsychotic treatment lurasidone, which is to undergo Phase III tests in South Korea and Taiwan. The move was made possible after Japan's health ministry indicated it would acknowledge foreign trials if they include at least some Japanese patients. Dainippon said future trials abroad would be held in areas where the people are similar physically to Japanese. (Click here for more - a subscription may be required
You may also be interested in...
In the only device-related warning letter released by the US FDA this week, Avazo Healthcare was selling two COVID-19 antigen tests without approval, clearance or authorization from the agency.
A sharp decline in the number of in-person facility inspections has forced the FDA to consider creative techniques for remotely evaluating manufacturer compliance during the COVID-19 pandemic. This and other stories topped our list of most-read Medtech Insight articles in November.
A package of health proposals intended to build up the EU’s resilience to health threats while strengthening the competitiveness of Europe’s pharmaceutical industry and ensuring access to affordable drugs takes a major step through the legislative process this week.